论文部分内容阅读
目的:探讨乳腺癌新辅助化疗疗效与激素受体之间的关系。方法:收集2010年1月至2013年12月期间,我院接受新辅助化疗的乳腺癌患者48例,采用Elivision法测定化疗前后患者的ER与PR表达情况,并评价其与PCR之间的相关性。结果:本组48例患者化疗后病理缓解率为81.25%,其中,PCR率为18.75;ER与PR表达与PCR之间无明显相关性。结论:新辅助化疗方案治疗乳腺癌可获得较大比例的PCR,但对ER及PR表达无影响。
Objective: To investigate the relationship between neoadjuvant chemotherapy and hormone receptor in breast cancer. Methods: Forty-eight patients with breast cancer who underwent neoadjuvant chemotherapy in our hospital from January 2010 to December 2013 were enrolled in this study. The expression of ER and PR in patients before and after chemotherapy was measured by Elivision and the correlation between them and PCR Sex. Results: The pathological remission rate of the 48 patients after chemotherapy was 81.25%, of which the PCR rate was 18.75. There was no significant correlation between ER and PR expression and PCR. Conclusion: Neoadjuvant chemotherapy regimen for breast cancer can obtain a large proportion of PCR, but has no effect on ER and PR expression.